Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ryan Joseph Sullivan, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA229851 (SULLIVAN, RYAN J) May 17, 2018 - Apr 30, 2022
    Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
    Role: Principal Investigator
  2. UH2CA207355 (SULLIVAN, RYAN J) May 10, 2018 - Dec 31, 2020
    Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patients
    Role: Principal Investigator
  3. R01CA193970 (SULLIVAN, RYAN J) Dec 8, 2015 - Nov 30, 2021
    Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286. PMID: 24983357.
    Citations: 25     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  2. Sullivan RJ, Fisher DE. Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am. 2014 Jun; 28(3):437-53. PMID: 24880940.
    Citations: 17     Fields:    Translation:HumansCells
  3. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53. PMID: 24746818; PMCID: PMC4079008.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  4. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 01; 120(11):1695-701. PMID: 24577748.
    Citations: 95     Fields:    Translation:Humans
  5. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Apr 15; 120(8):1194-202. PMID: 24474568; PMCID: PMC4038645.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  6. Panka DJ, Mier JW, Sullivan RJ. Assaying for BRAF V600E in tissue and blood in melanoma. Methods Mol Biol. 2014; 1102:117-36. PMID: 24258977.
    Citations: 3     Fields:    Translation:HumansCells
  7. Sullivan RJ, Atkins MB. Emerging clinical issues in melanoma in the molecularly targeted era. Methods Mol Biol. 2014; 1102:11-26. PMID: 24258971.
    Citations:    Fields:    Translation:Humans
  8. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8. PMID: 24265154.
    Citations: 237     Fields:    Translation:HumansCellsCTClinical Trials
  9. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013 Oct 01; 19(19):5283-91. PMID: 24089441.
    Citations: 32     Fields:    Translation:HumansCells
  10. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. PMID: 23913718; PMCID: PMC3986037.
    Citations: 80     Fields:    Translation:Humans
  11. Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med. 2013 Jul 11; 369(2):173-83. PMID: 23841733.
    Citations: 11     Fields:    Translation:HumansCells
  12. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32. PMID: 23716015.
    Citations: 50     Fields:    Translation:Humans
  13. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31. PMID: 23307859; PMCID: PMC3752683.
    Citations: 404     Fields:    Translation:HumansCells
  14. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013 Apr; 49(6):1297-304. PMID: 23290787.
    Citations: 148     Fields:    Translation:HumansCells
  15. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012 Nov-Dec; 35(9):711-5. PMID: 23090080.
    Citations: 8     Fields:    Translation:Humans
  16. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012 Jan; 35(1):66-72. PMID: 22130161.
    Citations: 51     Fields:    Translation:Humans
  17. Sullivan RJ, Flaherty KT. BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer. 2011; 2011:423239. PMID: 22175026.
    Citations: 13     
  18. DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, Sullivan RJ, Atkins MB. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res. 2011 Aug; 21(4):364-9. PMID: 21540750.
    Citations: 3     Fields:    Translation:Humans
  19. Mollberg NM, Glenn C, John J, Wise SR, Sullivan R, Vafa A, Snow NJ, Massad MG. Appropriate use of emergency department thoracotomy: implications for the thoracic surgeon. Ann Thorac Surg. 2011 Aug; 92(2):455-61. PMID: 21704969.
    Citations: 9     Fields:    Translation:Humans
  20. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e615-22. PMID: 21658854.
    Citations: 87     Fields:    Translation:Humans
  21. Frankenthaler A, Sullivan RJ, Wang W, Renzi S, Seery V, Lee MY, Atkins MB. Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. Melanoma Res. 2010 Dec; 20(6):496-500. PMID: 20823779.
    Citations: 7     Fields:    Translation:Humans
  22. Sullivan RJ, Pantanowitz L. New drug targets in Kaposi sarcoma. Expert Opin Ther Targets. 2010 Dec; 14(12):1355-66. PMID: 21043836.
    Citations: 4     Fields:    Translation:HumansCells
  23. Panka DJ, Sullivan RJ, Mier JW. An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res. 2010 Oct; 20(5):401-7. PMID: 20679909.
    Citations: 9     Fields:    Translation:HumansCells
  24. Sullivan RJ, Atkins MB. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opin Investig Drugs. 2010 Oct; 19(10):1205-16. PMID: 20687784.
    Citations: 7     Fields:    Translation:HumansCells
  25. Sullivan RJ, Atkins MB. Cytokine therapy in melanoma. J Cutan Pathol. 2010 Apr; 37 Suppl 1:60-7. PMID: 20482677.
    Citations: 2     Fields:    Translation:Humans
  26. Sullivan RJ, Pantanowitz L, Dezube BJ. Studying Rac1-induced tumorigenesis suggests antioxidants may help prevent and treat Kaposi's sarcoma. Future Oncol. 2009 Sep; 5(7):949-52. PMID: 19792964.
    Citations:    Fields:    
  27. Sullivan RJ, Atkins MB. Molecular-targeted therapy in malignant melanoma. Expert Rev Anticancer Ther. 2009 May; 9(5):567-81. PMID: 19445574.
    Citations: 6     Fields:    Translation:HumansCells
  28. Sullivan RJ, Pantanowitz L, Dezube BJ. Targeted therapy for Kaposi sarcoma. BioDrugs. 2009; 23(2):69-75. PMID: 19489649.
    Citations: 18     Fields:    Translation:HumansCells
  29. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008 Nov 01; 47(9):1209-15. PMID: 18808357; PMCID: PMC2700291.
    Citations: 39     Fields:    Translation:HumansCells
  30. Karmy-Jones R, Holevar M, Sullivan RJ, Fleisig A, Jurkovich GJ. Residual hemothorax after chest tube placement correlates with increased risk of empyema following traumatic injury. Can Respir J. 2008 Jul-Aug; 15(5):255-8. PMID: 18716687.
    Citations: 15     Fields:    Translation:Humans
  31. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol. 2008 Jun; 83(6):498-503. PMID: 18260115.
    Citations: 19     Fields:    Translation:HumansCells
  32. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ. Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci. 2007 Oct; 334(4):317-9. PMID: 18030193.
    Citations:    Fields:    Translation:HumansCells
  33. Braza JM, Sullivan RJ, Bhargava P, Pantanowitz L, Dezube BJ. Images in HIV/AIDS. Pericardial primary effusion lymphoma. AIDS Read. 2007 May; 17(5):250-2. PMID: 17532660.
    Citations: 1     Fields:    Translation:Humans
  34. Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ. Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs. 2007 Apr; 16(4):495-504. PMID: 17371197.
    Citations: 2     Fields:    Translation:HumansAnimals
  35. Dezube BJ, Sullivan R, Koon HB. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science. J Cell Physiol. 2006 Dec; 209(3):659-62. PMID: 17001705.
    Citations: 8     Fields:    Translation:HumansCells
  36. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol. 2006 Sep; 18(5):456-62. PMID: 16894293.
    Citations: 7     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sullivan's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (186)
Co-Authors (33)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.